• Profile

Methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients: Results from the MOTION trial

Intensive Care Medicine Feb 07, 2020

Patel PB, Brett SJ, O’Callaghan D, et al. - Whether opioid-induced constipation (OIC) in critical care patients could be reversed with methylnaltrexone, a pure peripheral mu-opioid receptor antagonist, was determined in this multi-centre, double blind, randomised placebo-controlled trial, the MOTION trial. This study was performed with adult ICU patients who were mechanically ventilated, taking opioids and were constipated despite previous administration of regular laxatives according to local bowel management protocol. Overall 41 patients were randomized to methylnaltrexone and 43 to placebo. The groups showed no significant variation in time to rescue-free laxation. No evidence favoring methylnaltrexone addition to regular laxatives for the management of OIC in critically ill patients was found in this study; however, wide confidence interval was reported and a clinically significant difference could not be excluded.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen